Glucagon-like peptide-1 receptor agonists for major cardiovascular and kidney outcomes in type 1 diabetes - PubMed
3 hours ago
- #cardiovascular outcomes
- #GLP-1 receptor agonists
- #type 1 diabetes
- GLP-1 receptor agonists (GLP-1RAs) show potential benefits for type 1 diabetes patients.
- Study based on national electronic health records of 174,678 type 1 diabetes patients.
- GLP-1RA initiation linked to lower risks of major adverse cardiovascular events (5-year risk difference: -0.7%).
- Reduced risk of end-stage kidney disease observed (5-year risk difference: -0.3%).
- No increased risks of diabetic ketoacidosis or severe hypoglycemia hospitalization.
- Findings suggest GLP-1RAs may improve cardiorenal outcomes without safety concerns.